IMA
Price:
$6.78
Market Cap:
$75.81M
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Industry
Biotechnology
IPO Date
1998-02-27
Stock Exchange
NASDAQ
Ticker
IMA
According to ImageneBio Inc’s latest financial reports and current stock price. The company's current Enterprise Value is 23.20M. This represents a change of -97.20% compared to the average of 829.34M of the last 4 quarters.
The mean historical Enterprise Value of ImageneBio Inc over the last ten years is 7.04B. The current 23.20M Enterprise Value has changed -67.04% with respect to the historical average. Over the past ten years (40 quarters), IMA's Enterprise Value was at its highest in in the June 2021 quarter at 5.78B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
7.04B
Median
5.19B
Minimum
877.46M
Maximum
13.81B
Discovering the peaks and valleys of ImageneBio Inc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.60%
Maximum Annual Enterprise Value = 13.81B
Minimum Annual Increase = -78.78%
Minimum Annual Enterprise Value = 877.46M
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 917.85M | 4.60% |
| 2023 | 877.46M | -20.30% |
| 2022 | 1.10B | -78.78% |
| 2021 | 5.19B | -61.86% |
| 2020 | 13.60B | -1.16% |
| 2019 | 13.76B | -0.34% |
The current Enterprise Value of ImageneBio Inc (IMA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
965.41M
5-year avg
4.34B
10-year avg
7.04B
ImageneBio Inc’s Enterprise Value is less than Connect Biopharma Holdings Limited (102.22M), less than InflaRx N.V. (51.57M), less than Kalaris Therapeutics Inc (69.88M), less than Shattuck Labs, Inc. (101.48M), greater than Context Therapeutics Inc. (11.29M), less than Sutro Biopharma, Inc. (31.59M), less than Artiva Biotherapeutics, Inc. (78.84M), less than Ovid Therapeutics Inc. (96.01M), less than Metagenomi, Inc. Common Stock (83.35M), less than Quince Therapeutics, Inc. (201.00M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 102.22M | $141.98M | |
| 51.57M | $74.52M | |
| 69.88M | $110.72M | |
| 101.48M | $142.27M | |
| 11.29M | $94.64M | |
| 31.59M | $79.86M | |
| 78.84M | $92.66M | |
| 96.01M | $115.21M | |
| 83.35M | $67.21M | |
| 201.00M | $200.45M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImageneBio Inc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImageneBio Inc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is ImageneBio Inc's Enterprise Value?
What is the highest Enterprise Value for ImageneBio Inc (IMA)?
What is the 3-year average Enterprise Value for ImageneBio Inc (IMA)?
What is the 5-year average Enterprise Value for ImageneBio Inc (IMA)?
How does the current Enterprise Value for ImageneBio Inc (IMA) compare to its historical average?